AZN logo

AZN

AstraZeneca PLC

$203.49
$0.00(0.00%)
76
Overall
80
Value
72
Tech
--
Quality
How is this score calculated?
Market Cap
$600.53B
Volume
2.05M
52W Range
$61.24 - $212.71
Target Price
$205.39

Company Overview

Mkt Cap$600.53BPrice$203.49
Volume2.05MChange+0.00%
P/E Ratio85.4Open$199.78
Revenue$54.1BPrev Close$203.49
Net Income$7.0B52W Range$61.24 - $212.71
Div Yield5.30%Target$205.39
Overall76Value80
Quality--Technical72

No chart data available

About AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Sector: Healthcare
Industry: Drug Manufacturers - Major

Latest News

AstraZeneca (AZN) Receives a Buy from Goldman Sachs

In a report released yesterday, Rajan Sharma from Goldman Sachs maintained a Buy rating on AstraZeneca, with a price target of p16,600.00. The comp...

TipRanks Auto-Generated Intelligence Newsdesk2 days ago

AstraZeneca Completes Early Obesity Trial for AZD6234, Nudging Long-Term Growth Hopes

TipRanks Clinical-Trials-Auto-Generated Newsdesk2 days ago

AZN, NVO, NVS: What Does Trump’s New 100% Tariff Mean for Pharma Giants?

Solomon Oladipupo2 days ago

AstraZeneca’s New Cancer Combo Trial Signals Steady Progress in Antibody Drug Conjugates

TipRanks Clinical-Trials-Auto-Generated Newsdesk3 days ago

AstraZeneca (AZN) Receives a Buy from Jefferies

TipRanks Auto-Generated Intelligence Newsdesk6 days ago
ABCD
1SymbolPriceChangeVol
2AZN$203.490%2.05M
3
4
5
6

Get AstraZeneca PLC Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.